Filed: May 05, 2015
Latest Update: Mar. 02, 2020
Summary: Case: 14-13131 Date Filed: 05/05/2015 Page: 1 of 13 [PUBLISH] IN THE UNITED STATES COURT OF APPEALS FOR THE ELEVENTH CIRCUIT _ No. 14-13131 _ D.C. Docket No. 1:04-cv-03294-CAP FEDERAL TRADE COMMISSION, Plaintiff-Appellee, CERTUSBANK, N.A., Plaintiff, versus NATIONAL UROLOGICAL GROUP, INC., et al., d.b.a. Warner Laboratories, Defendants, HI-TECH PHARMACEUTICALS, INC., Corporation, JARED WHEAT, individually and as officer of the corporation, STEPHEN SMITH, individually and as officer of National U
Summary: Case: 14-13131 Date Filed: 05/05/2015 Page: 1 of 13 [PUBLISH] IN THE UNITED STATES COURT OF APPEALS FOR THE ELEVENTH CIRCUIT _ No. 14-13131 _ D.C. Docket No. 1:04-cv-03294-CAP FEDERAL TRADE COMMISSION, Plaintiff-Appellee, CERTUSBANK, N.A., Plaintiff, versus NATIONAL UROLOGICAL GROUP, INC., et al., d.b.a. Warner Laboratories, Defendants, HI-TECH PHARMACEUTICALS, INC., Corporation, JARED WHEAT, individually and as officer of the corporation, STEPHEN SMITH, individually and as officer of National Ur..
More
Case: 14-13131 Date Filed: 05/05/2015 Page: 1 of 13
[PUBLISH]
IN THE UNITED STATES COURT OF APPEALS
FOR THE ELEVENTH CIRCUIT
________________________
No. 14-13131
________________________
D.C. Docket No. 1:04-cv-03294-CAP
FEDERAL TRADE COMMISSION,
Plaintiff-Appellee,
CERTUSBANK, N.A.,
Plaintiff,
versus
NATIONAL UROLOGICAL GROUP, INC., et al.,
d.b.a. Warner Laboratories,
Defendants,
HI-TECH PHARMACEUTICALS, INC.,
Corporation,
JARED WHEAT,
individually and as officer of the corporation,
STEPHEN SMITH,
individually and as officer of National Urological
Group, Inc. and National Institute for Clinical
Weight Loss, Inc.,
M.D. TERRILL MARK WRIGHT,
Individually,
Case: 14-13131 Date Filed: 05/05/2015 Page: 2 of 13
Defendants-Appellants.
________________________
Appeals from the United States District Court
for the Northern District of Georgia
________________________
(May 5, 2015)
Before TJOFLAT, WILLIAM PRYOR, and BARKSDALE, ∗ Circuit Judges.
WILLIAM PRYOR, Circuit Judge:
In this appeal, we must decide whether the district court abused its discretion
when it held Hi-Tech Pharmaceuticals, Inc., Jared Wheat, Stephen Smith, and Dr.
Terrill Mark Wright in contempt for violating injunctions that prohibit them from
making any representation about weight-loss products unless they “possess[] and
rel[y] upon competent and reliable scientific evidence that substantiates the
representation.” Hi-Tech, Wheat, Smith, and Wright submitted evidence to support
the challenged representations and an expert declaration that the representations
were substantiated by “competent and reliable scientific evidence.” But the district
court refused to consider the evidence. The district court ruled that because it had
required Hi-Tech, Wheat, Smith, and Wright to produce clinical trials to
substantiate different representations about different weight-loss products in an
∗
Honorable Rhesa H. Barksdale, United States Circuit Judge for the Fifth Circuit, sitting by
designation.
2
Case: 14-13131 Date Filed: 05/05/2015 Page: 3 of 13
earlier stage of this litigation, they were collaterally estopped from presenting new
kinds of evidence to satisfy the standard of “competent and reliable scientific
evidence” and instead had to produce clinical trials to substantiate the challenged
representations. After Hi-Tech, Wheat, Smith, and Wright failed to produce
clinical trials to substantiate their representations, the district court held them in
contempt. Because the district court misapplied the doctrine of collateral estoppel,
we vacate and remand.
I. BACKGROUND
We divide our discussion of the background in two parts. First, we discuss
the initial litigation between the Federal Trade Commission and Hi-Tech, Wheat,
Smith, and Wright. Second, we discuss the contempt proceedings that gave rise to
this appeal.
A. Initial Litigation.
In 2004, the Commission filed a complaint against Hi-Tech, Hi-Tech’s Chief
Executive Officer, Wheat, Hi-Tech’s Senior Vice President, Smith, and Wright for
violations of sections 5 and 12 of the Federal Trade Commission Act, 15 U.S.C.
§§ 45(a), 52. The Commission alleged that the defendants made unsubstantiated
representations about two weight-loss products, “Thermalean” and “Lipodrene.”
The Commission alleged that the defendants lacked adequate substantiation for
3
Case: 14-13131 Date Filed: 05/05/2015 Page: 4 of 13
their representations that Thermalean “is an effective treatment for obesity,” “is
equivalent or superior to the prescription weight loss drugs Xenical, Meridia, and
Fastin in providing weight loss benefits,” “causes rapid and substantial weight loss,
including as much as 30 pounds in 2 months,” and “causes users to lose 19% of
total body weight, lose 20-35% of abdominal fat, reduce their overall fat by 40-
70%, [and] decrease their stored fat by 300%,” and that Lipodrene “causes
substantial weight loss, including as much as 125 pounds” and “enables users to
lose up to 42% of total body fat and 19% of total body weight, and to increase their
metabolic rate by up to 50%.”
In 2008, the district court granted summary judgment in favor of the
Commission. The district court concluded that the defendants had violated the
Trade Commission Act because they had not substantiated their representations
with clinical trials of the weight-loss products instead of ingredients in the
products. The district court entered a final judgment and permanent injunction
against Hi-Tech, Wheat, and Smith, and a separate final judgment and permanent
injunction against Wright based on his unsubstantiated endorsements of the
products.
The injunctions prohibited the defendants from making any representation
that a weight-loss product “causes rapid or substantial loss of weight or fat” or
4
Case: 14-13131 Date Filed: 05/05/2015 Page: 5 of 13
“affects human metabolism, appetite, or body fat,” unless the defendants “possess[]
and rel[y] upon competent and reliable scientific evidence that substantiates the
representation.” The injunctions defined “competent and reliable scientific
evidence” to mean “tests, analyses, research, studies, or other evidence based on
the expertise of professionals in the relevant area, that has been conducted and
evaluated in an objective manner by persons qualified to do so, using procedures
generally accepted in the profession to yield accurate and reliable results.” The
injunctions did not mention any requirement to produce clinical trials to
substantiate weight-loss representations.
B. Contempt Proceedings.
After Hi-Tech, Wheat, Smith, and Wright continued to promote weight-loss
products, the Commission moved the district court in 2011 to order Hi-Tech,
Wheat, and Smith to show cause why they should not be held in contempt for
making unsubstantiated representations about four products, “Fastin,” “Stimerex-
ES,” “Benzedrine,” and a reformulated version of “Lipodrene.” The Commission
alleged that Hi-Tech, Wheat, and Smith lacked adequate substantiation for the
following representations:
The “World’s Most Advanced Weight Loss Aid Ever Developed!” . . .
(Fastin print ad);
5
Case: 14-13131 Date Filed: 05/05/2015 Page: 6 of 13
“[A] Truly Extraordinary Weight Loss Product . . . Fastin is unlike
anything you have ever tried before and will help you lose weight.”
. . . (Fastin print ad);
A “Revolutionary Diet Aid Taking the Market by Storm!” . . . (Fastin
product page, www.hitechpharma.com);
“[A] pharmaceutical-grade dietary supplement indicated for weight
loss in extremely overweight individuals.” . . . (Fastin product
packaging); . . .
An “EXTREMELY POTENT DIET AID! DO NOT CONSUME
UNLESS RAPID . . . WEIGHT LOSS [IS] YOUR DESIRED
RESULT.” . . . (Fastin product packaging) . . .
“[I]s a revolutionary weight loss formula scientifically engineered to
help people lose weight and feel great!”. . . (Lipodrene print ad);
Is “the benchmark standard for the weight loss industry.” . . .
(Lipodrene product page, www.hitechpharma.com);
“[I]s the Gold Standard in the weight loss industry for one simple
Reason . . . It Works!”. . . ;
“[W]ill cause rapid . . . weight loss with usage.” . . . (Lipodrene
product packaging); . . .
“The World’s Most Advanced Weight Loss Aid Ever Developed!”
[Lipodrene product packaging] . . .
Is an “Extreme Fat Burner.” . . . (Fastin print ad);
Is a “Novel Fat Burner.” . . . [Fastin print ad];
“[I]s the Gold Standard by which all Fat Burners should be judged.”
. . . [Fastin print ad];
Is a “Rapid Fat Burner.” . . . (Fastin product packaging); . . .
6
Case: 14-13131 Date Filed: 05/05/2015 Page: 7 of 13
Is a “Rapid Fat Loss Catalyst.” . . . (Fastin product packaging) . . .
A “Novel Fat Burner that Helps Melt Away Pounds.” . . . (Lipodrene
print ad);
“[A] Fat Assassin unlike any other ‘Fat Burner.’” . . . [Lipodrene print
ad];
“[T]he best fat-burner [sic] in existence.” . . . [Lipodrene print ad];
“[T]he ‘Gold Standard’ by which all fat loss products are judged.” . . .
(Print ad for multiple Hi-Tech products including Lipodrene);
“Hi-Tech’s Flagship Fat Loss Product with 25 mg Ephedra Extract –
Annihilate Fat.” . . . (Lipodrene product page,
www.hitechpharma.com) . . .
“[T]he right move to strip away fat.” . . . [Lipodrene product page];
...
“The Strongest Fat Burner/Energizer Ever Produced.” . . .
(Benzedrine print ad); . . .
“[T]he most potent Fat Burner/Energizer known to man.” [Benzedrine
print ad] . . .
Has “Unmatched Anorectic Activity to Manage Caloric Intake.” . . .
(Benzedrine product page, www.hitechpharma.com); . . .
Is “the first anorectic supplement ever produced.” . . . (Benzedrine
product packaging) . . .
“[U]ndeniably the most powerful, fat loss . . . formula ever created.” .
. . (Print ad for multiple Hi-Tech products including Stimerex-ES);
“[T]he Strongest Fat Burner/Energizer to ever hit the market!” . . .
(Stimerex-ES print ad); . . .
7
Case: 14-13131 Date Filed: 05/05/2015 Page: 8 of 13
“The Ultimate Fat Burner Ever Created.” . . . (Stimerex-ES product
page, www.hitechpharma.com) . . .
“Curbs the Appetite!” . . . [Fastin ad] . . .
“Increases the metabolic rate, promoting thermogenesis (The Burning
of Stored Body Fat).” . . . [Fastin ad]; . . .
“[H]as both immediate and delayed release profiles for appetite
suppression, energy and weight loss.” [Fastin ad] . . .
Has “Unmatched Anorectic Activity to Manage Caloric Intake.” . . .
(Benzedrine product page, www.hitechpharma.com); and
Is “the first anorectic supplement ever produced.” . . . (Benzedrine
product packaging).
The Commission also moved to hold Wright in contempt for his endorsement of
Fastin.
In response, the defendants submitted evidence to support their
representations and an expert’s declaration that the representations were
substantiated by “competent and reliable scientific evidence,” but the district court
refused to consider the defendants’ evidence. The district court explained, based on
the “law of the case,” that “[t]he only evidence that will be relevant to show
whether the defendants ‘possess[ed] and rel[ied] upon competent and reliable
scientific evidence’ to substantiate any representation is the kind of evidence . . .
previously adopted by the court.” In an earlier stage of the litigation, the district
8
Case: 14-13131 Date Filed: 05/05/2015 Page: 9 of 13
court ruled that “some form of clinical trial must have been conducted on the
product itself or an exact duplicate of the product to substantiate the defendants’
claims regarding the overall product.” Because the defendants had not produced
clinical trials on the four products at issue in the contempt proceedings, the district
court granted the motion to show cause. The district court later clarified that it
based its ruling that only clinical trials could establish “competent and reliable
scientific evidence” on the doctrine of collateral estoppel, instead of the “law of the
case.”
After Hi-Tech, Wheat, Smith, and Wright failed to produce clinical trials on
the weight-loss products, the district court held them in contempt for violating the
injunctions. The district court held Hi-Tech, Wheat, and Smith jointly and
severally liable for approximately $40 million in sanctions, which equaled Hi-
Tech’s gross receipts for the four products during the relevant time period. The
district court also held Wright liable for $120,000, which reflected the sum Hi-
Tech paid him for endorsing Fastin during the relevant time period.
II. STANDARD OF REVIEW
We review a sanction for civil contempt for abuse of discretion. McGregor
v. Chierico, 206 F.3d 1378, 1383 (11th Cir. 2000). “A district court abuses its
discretion if it applies an incorrect legal standard, applies the law in an
9
Case: 14-13131 Date Filed: 05/05/2015 Page: 10 of 13
unreasonable or incorrect manner, follows improper procedures in making a
determination, or makes findings of fact that are clearly erroneous.” Citizens for
Police Accountability Political Comm. v. Browning, 572 F.3d 1213, 1216–17 (11th
Cir. 2009).
III. DISCUSSION
The district court abused its discretion when it held the defendants in
contempt. The district court misapplied the doctrine of collateral estoppel when it
refused to consider the defendants’ evidence of substantiation. Collateral estoppel
“bars successive litigation of an issue of fact or law actually litigated and resolved
in a valid court determination essential to the prior judgment, even if the issue
recurs in the context of a different claim.” Taylor v. Sturgell, 553 U.S. 880, 892,
128 S. Ct. 2161, 2171 (2008) (internal quotation marks and citation omitted). We
apply collateral estoppel only when four criteria are satisfied:
(1) the issue at stake is identical to the one involved in the prior
litigation; (2) the issue was actually litigated in the prior suit; (3) the
determination of the issue in the prior litigation was a critical and
necessary part of the judgment in that action; and (4) the party against
whom the earlier decision is asserted had a full and fair opportunity to
litigate the issue in the earlier proceeding.
Miller’s Ale House, Inc. v. Boynton Carolina Ale House, LLC, 702 F.3d 1312,
1318 (11th Cir. 2012). To establish that an issue is not identical to one resolved in
previous litigation, a party “need only point to one material differentiating fact that
10
Case: 14-13131 Date Filed: 05/05/2015 Page: 11 of 13
would alter the legal inquiry,” CSX Transp., Inc. v. Bhd. of Maint. of Way Emps.,
327 F.3d 1309, 1317 (11th Cir. 2003). The defendants can easily do so because the
level of substantiation the injunctions require for the representations at issue in the
contempt proceedings is not “identical” to any issue the district court decided in
the earlier litigation.
The issue decided in the earlier litigation involved different representations,
different products, and the interpretation of a different legal standard from the issue
the district court prevented Hi-Tech, Wheat, Smith, and Wright from litigating in
the contempt proceedings. The district court previously ruled that Hi-Tech, Wheat,
Smith, and Wright needed to produce clinical trials that substantiated their
representations about Thermalean and an older version of Lipodrene under the
Trade Commission Act. In the contempt proceedings, by contrast, the district court
held that Hi-Tech, Wheat, Smith, and Wright were collaterally estopped from
litigating the level of substantiation the injunctions require for different
representations about Fastin, Stimerex-ES, Benzedrine, and the reformulated
Lipodrene.
The differences between the issue decided in the previous litigation and the
issue the defendants were prevented from litigating in the contempt proceedings
“point to” at least “one material differentiating fact that would alter the legal
11
Case: 14-13131 Date Filed: 05/05/2015 Page: 12 of 13
inquiry,” id. at 1317. The district court explained in the previous litigation that the
“competent and reliable scientific evidence” standard imposed by the injunctions is
“context specific” and “permits different variations . . . depending on what
pertinent professionals would require for the particular claim made.” The district
court further explained that “the size, duration or protocol of a scientific study, the
number or type of scientific studies required to substantiate a claim, and the proper
mechanism for extrapolating results from studies will obviously vary from
circumstance to circumstance depending upon the expert evidence presented.” That
the representations at issue in the previous litigation involved different products,
referenced other weight-loss products by name, and were far more specific than
those at issue in the contempt proceedings accordingly “alter[s] the legal inquiry,”
id. The issue decided in the previous litigation is not “identical,” Miller’s Ale
House,
Inc., 702 F.3d at 1318, to the issue the district court prevented the
defendants from litigating in the contempt proceedings. The district court erred
when it applied the doctrine of collateral estoppel.
Hi-Tech, Wheat, Smith, and Wright also argue that the district court erred by
adopting a stricter standard for substantiation than the injunctions require and by
relying on evidence of privileged communications, but those questions are
premature. On remand, the district court must exercise its discretion to determine
12
Case: 14-13131 Date Filed: 05/05/2015 Page: 13 of 13
the admissibility of any evidence offered by the Commission and by the contempt
defendants and make findings about whether any evidence of substantiation, if
admissible, satisfies the standard of the injunctions for “competent and reliable
scientific evidence.” We hold only that the district court misapplied collateral
estoppel when it barred Hi-Tech, Wheat, Smith, and Wright from presenting
evidence to prove their compliance with the injunctions.
IV. CONCLUSION
We VACATE the order holding Hi-Tech, Wheat, Smith, and Wright in
contempt and REMAND for further proceedings consistent with this opinion.
13
